Tomas Buchler (Tomáš Büchler)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 20

Top Venues

Targeted oncology

Cancers

Cancer management and research

Oncoimmunology

This page only lists publications with an associated author ORCID identifier.

Publications

Tomas Buchler, Alexandr Poprach
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted oncology 19 (2) (2024)
Tomas Buchler, Alexandr Poprach
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted oncology 19 (2) (2024)
Tomas Buchler, Alexandr Poprach
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted oncology (2024)
Tomas Buchler, Alexandr Poprach
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted oncology 19 (2) (2024)
Tomas Buchler, Alexandr Poprach
Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted oncology 19 (2) (2024)
Alexandr Poprach, Igor Kiss, Michal Stanik, Tamara Barusova, Lenka Pospisilova, Ondrej Fiala, Jindrich Kopecky, Igor Richter, Bohuslav Melichar, Hana Studentova, Radek Lakomy, Milos Holanek, Aneta Rozsypalova, Anezka Zemanková, Marek Svoboda, Tomas Buchler
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. Targeted oncology (2023)
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study. Cancers 14 (17) (2022)
Manish A Shah, Anghel Adrian Udrea, Igor Bondarenko, Was Mansoor, Raquel Guardeño Sánchez, Tomasz Sarosiek, Silvia Bozzarelli, Michael Schenker, Carlos Gomez-Martin, Carys Morgan, Mustafa Özgüroğlu, Joanna Pikiel, Haralabos P Kalofonos, Elzbieta Wojcik, Tomas Buchler, Daniel Swinson, Irfan Cicin, Mano Joseph, Ihor Vynnychenko, Alexander Valerievich Luft, Peter C Enzinger, Tomas Salek, Christos Papandreou, Christophe Tournigand, Evaristo Maiello, Ran Wei, David Ferry, Ling Gao, Joana M Oliveira, Jaffer A Ajani
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers 14 (5) (2022)
Lola-Jade Palmieri, Tomas Buchler, Antoine Meyer, Veronika Veskrnova, Ondrej Fiala, Petr Brabec, Jana Baranova, Romain Coriat
Impact of Delaying the Addition of Anti-EGFR in First Line of RAS Wild-Type Metastatic Colorectal Cancer: A Propensity-Weighted Pooled Data Analysis. Cancers 14 (6) (2022)
Tomas Buchler, Marie Kopecka, Anezka Zemankova, Markéta Wiesnerová, Eva Streckova, Aneta Rozsypalova, Bohuslav Melichar, Alexandr Poprach, Igor Richter
Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. Targeted oncology 15 (5) (2021)
Tomas Buchler, Lukas Fiser, Jaroslava Benesova, Hana Jirickova, Jana Votrubova
Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases. Current oncology (Toronto, Ont.) 28 (5) (2021)
Ondrej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondřej Šorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomas Buchler
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib. Cancer management and research 13 (2021)
Alena Novakova-Jiresova, Katerina Kopeckova, Ludmila Boublikova, Renata Chloupkova, Bohuslav Melichar, Lubos Petruzelka, Jindrich Finek, Ondrej Fiala, Peter Grell, Stanislav Batko, Zdenek Linke, Igor Kiss, Jana Prausova, Tomas Buchler
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. Cancer management and research 12 (2020)
Tomas Buchler, Igor Kiss, Jana Hornova, Ondrej Fiala, Marketa Wiesnerova, Michal Svoboda, Jiri Silar, Katerina Kopeckova, Alexandr Poprach, Jindrich Finek, Lubos Petruzelka, Bohuslav Melichar
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. Targeted oncology 15 (2) (2020)
Pavel Vodicka, Sona Vodenkova, Tomas Buchler, Ludmila Vodickova
DNA repair capacity and response to treatment of colon cancer. Pharmacogenomics 20 (17) (2019)
Ondrej Fiala, Veronika Veskrnova, Renata Chloupkova, Alexandr Poprach, Igor Kiss, Katerina Kopeckova, Ladislav Dusek, Lubomir Slavicek, Milan Kohoutek, Jindrich Finek, Marek Svoboda, Lubos Petruzelka, Ludmila Boubliková, Josef Dvorak, Bohuslav Melichar, Tomas Buchler
Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted oncology 13 (6) (2019)
Katerina Jiraskova, David J Hughes, Stefanie Brezina, Tanja Gumpenberger, Veronika Veskrnova, Tomas Buchler, Michaela Schneiderova, Miroslav Levy, Vaclav Liska, Sona Vodenkova, Cornelia Di Gaetano, Alessio Naccarati, Barbara Pardini, Veronika Vymetálková, Andrea Gsur, Pavel Vodicka
Functional Polymorphisms in DNA Repair Genes Are Associated with Sporadic Colorectal Cancer Susceptibility and Clinical Outcome. International journal of molecular sciences 20 (1) (2018)
Tomas Buchler, Pavel Vasek, Radek Spisek, Pavel Skrobanek, Vaclav Horejsi
Tumour devascularisation as a potential immunotherapeutic strategy. Oncoimmunology 8 (1) (2018)
Alexandr Poprach, Radek Lakomy, Zbynek Bortlicek, Bohuslav Melichar, Tomas Pavlik, Ondrej Slaby, Rostislav Vyzula, Marek Svoboda, Igor Kiss, Hana Studentova, Milada Zemanova, Ondrej Fiala, Katerina Kubackova, Ladislav Dusek, Jana Hornova, Tomas Buchler, null null
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & aging 33 (9) (2017)
Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk, Tomas Buchler
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC cancer 17 (1) (2017)

Tomas Buchler.css-eqlu8i{font-size:small;padding-left:4px;} (Tomáš Büchler)

Publication Activity (10 Years)

Top Topics

Top Venues

Tomas Buchler (Tomáš Büchler)